Please select the outcome measures that correspond to the clinical trial below.
Title: LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks
Brief Summary: The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.


Options:
A: The mean acute angioedema attack rate (12 weeks)
B: Incidence of Cardiac Ischemia Events in Participants Predisposed to Cardiac Ischemia Events With Concomitant Firazyr (Icatibant) Administration (From enrollment through study participation (Approximately 13 years)); Incidence of Hypotension for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Incidence of Swelling of Mucous Membranes for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Incidence of Bronchoconstriction for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Incidence of Aggravation of Pain for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Sexual Hormones Level Measurements- Tanner Staging for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Time to Complete Resolution of the Firazyr (Icatibant)-Treated Laryngeal Attacks (From enrollment through study participation (Approximately 13 years)); Incidence of Adverse Events (AE) Related to Firazyr (Icatibant)-Treated Laryngeal Attacks (From enrollment through study participation (Approximately 13 years)); Incidence of Adverse Drug Reactions (ADR) for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Incidence of Serious Adverse Events (SAE) for Firazyr (Icatibant) (From enrollment through study participation (Approximately 13 years)); Incidence of Pregnancy and Lactation Events During Firazyr (Icatibant) Exposure (From enrollment through study participation (Approximately 13 years)); Incidence of Adverse Events (AE) for Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Incidence of Adverse Drug Reactions (ADR) for Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Incidence of Serious Adverse Events (SAE) for Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Incidence of Thrombotic or Thromboembolic Events for Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Incidence of Pregnancy and Lactation Events During Cinryze (C1 Inhibitor [Human]) Exposure (From enrollment through study participation (Approximately 13 years)); Drug Exposure Data for Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Frequency of Hereditary Angioedema (HAE) Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Severity of Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Anatomic Location of Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Outcome of Severe or Laryngeal Hereditary Angioedema Attacks in Participants Treated With Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years)); Outcome of Hereditary Angioedema Attacks for Treatment With Cinryze (C1 Inhibitor [Human]) (From enrollment through study participation (Approximately 13 years))
C: Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period (12 weeks)
D: Time to Beginning of Substantial Relief of the Defining Symptom (Within 4 hours after initial treatment)

Answer: C